New drug BB102 takes on Hard-to-Treat liver cancer
NCT ID NCT07239986
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests BB102, a targeted drug that blocks a protein called FGFR4, in 60 adults with advanced liver cancer that has not responded to standard treatments. Participants must have a specific genetic marker (FGF19 overexpression). The study will measure how well the drug shrinks tumors and controls the disease, while monitoring safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BB102 (a targeted drug that blocks FGFR4 protein)
What this could lead to
If it works, this could provide a new treatment option for people with advanced liver cancer that has not responded to other therapies.
What could go wrong
This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, 230031, China
Contact Phone: •••-•••-••••
-
Zhongshan Hospital
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-••••